Table 5.

Active Clinical Trials for the Podocytopathies^*

Trial Identifier	Disease Entities	Therapy	Trial Design	Sponsor	Sites
NCT00065611	MCN, FSGS,     CG	Pulse dexamethasone	Open-label,     randomized     to 2 doses	NIDDK, Bethesda, Md	NIH Clinical Center, Bethes-     da, Md; Mayo Clinic,     Rochester, Minn
NCT00098020	MCN, FSGS,     DMS, CG	Isotretinoin	Open label,     randomized     to 2 doses	NIDDK	NIH Clinical Center, Bethes-     da, Md
NCT00135811	FSGS, CG	1. CSA 2. Pulse dexametha-     sone + mycophen-     olate mofetil	RCT	NIDDK	Multicenter (United States):     data coordinating center,     Cleveland Clinic, Cleve-     land, Ohio
NCT0019927	Proteinuric ne-     phropathies	Fluvastatin	RCT, active     control	Mario Negri Institute,     Bergamo, Italy	Multicenter (Italy): Mario Ne-     gri Insititute
NCT0040483	FSGS, CG	1. Prednisolone +     mycophenolate 2. Prednisolone +     chlorambucil	RCT	University of Hong     Kong, Hong Kong,     China	University of Hong Kong
NCT00464321	FSGS, CG	Anti-TGF- β1,2,3 hu-     manized monocle-     nal antibody     (GC1008)	Phase I, single     dose	Genzyme, San Fran-     cisco, Calif	Multicenter (USA and Eu-     rope), Genzyme, Boston,     Mass
NCT00550342	FSGS, primary     and recur-     rent; CG	Rituximab (anti-CD20     monoclonal anti-     body)	Open label, 4     doses	NIDDK	Indiana University, Indianapo-     lis
NCT003020536	FSGS	Tacrolimus	Randomized,     open label,     active control	Nanjing University     School of Medi-     Cine, China	Nanjing, China

^*Data are excerpted from trials listed at www.clinicaltrials.gov, limited to trials that are actively recruiting patients. Web site accessed May 30, 2008. MCN indicates minimal change nephropathy; FSGS, focal segmental glomerulosclerosis; DMS, diffuse mesangial sclerosis; CG, collapsing glomerulopathy; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; CSA, cyclosporine; and RCT, randomized controlled trial.